格劳科斯眼科
GKOS
164.84
-0.76
-0.46%
格劳科斯眼科
US · GKOS
#1500 按市值排名
上市于 2015
164.84
-0.76
-0.46%
实时 - 追踪5344个代码 - 心跳于544秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量增加了1家。
- 机构持股总比例下降了0.5个百分点。
机构持股
- 机构持股比例
- 104.08% -0.54pp
- 机构数量
- 437 +1
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund84.30%
Hedge Fund12.95%
Individual/Insider3.57%
Public Company3.40%
Government Pension Fund1.45%
Sovereign Wealth Fund0.85%
Private Company0.69%
Insurance Company0.32%
主要股东 截至 2026-06-30
BlackRock
16.18% · 9.54M 股
Janus Henderson Group plc
8.25% · 4.86M 股
Vanguard Portfolio Management, LLC
5.63% · 3.32M 股
PRIMECAP Management Company
5.16% · 3.04M 股
Vanguard Capital Management, LLC
5.04% · 2.97M 股
State Street Global Advisors
3.93% · 2.32M 股
Thomas Burns
2.90% · 1.71M 股
Millennium Management LLC
2.68% · 1.58M 股
Holocene Advisors, LP
2.57% · 1.51M 股
Geode Capital Management, LLC
2.48% · 1.46M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 21次买入 · 29次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Thomas Burns | Chairperson & CEO | 2.90% |
| David Hoffmeister | Independent Director | 0.14% |
| Mark Foley | Lead Independent Director | 0.09% |
| Aimee Weisner | Independent Director | 0.08% |
| Alex Thurman | Senior Vice President | 0.07% |
| Gilbert Kliman | Independent Director | 0.06% |
| Marc Stapley | Independent Director | 0.06% |
| Tomas Navratil | Chief Development Officer | 0.05% |
| Joseph Gilliam | President | 0.05% |
| Denice Torres | Independent Director | 0.03% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-10-04 | Tomas Navratil | Chief Development Officer | Intent to Sell (Form 144) | -1,527 | $164.45 |
| 2026-09-24 | Tomas Navratil | Chief Development Officer | Automatic Disposition | -1,615 | $151.70–154.88 |
| 2026-09-15 | Tomas Navratil | Chief Development Officer | Automatic Disposition | -1,457 | $163.20–172.00 |
| 2026-08-27 | Tomas Navratil | Chief Development Officer | Private Disposition | -10 | $182.50 |
| 2026-08-27 | Tomas Navratil | Chief Development Officer | Open Market Disposition | -13,734 | $180.25–181.19 |
| 2026-08-18 | Gilbert Kliman | Independent Director | Derivative Exercise and Sale | -2,500 | $25.77–190.00 |
| 2026-08-10 | Joseph Gilliam | President | Derivative Exercise and Sale | -60,000 | $48.46–180.49 |
| 2026-08-06 | Alex Thurman | Senior Vice President | Derivative Exercise and Sale | -20,000 | $33.81–180.13 |
| 2026-07-30 | Leana Wen | Independent Director | Open Market Disposition | -525 | $167.63 |
| 2026-07-15 | Alex Thurman | Senior Vice President | Derivative Exercise and Sale | -10,000 | $38.68–160.00 |
| 2026-07-08 | Alex Thurman | Senior Vice President | Derivative Exercise and Sale | -10,000 | $38.68–155.00 |
| 2026-07-05 | Alex Thurman | Senior Vice President | Derivative Exercise and Sale | -10,000 | $38.68–150.00 |
| 2026-06-30 | Tomas Navratil | Chief Development Officer | Automatic Disposition | -716 | $139.06 |
| 2026-06-24 | Thomas Burns | Chairperson & CEO | Sale to Issuer | -4,059 | $142.57 |
| 2026-06-24 | Joseph Gilliam | President | Sale to Issuer | -1,056 | $142.57 |
| 2026-06-24 | Tomas Navratil | Chief Development Officer | Sale to Issuer | -483 | $142.57 |
| 2026-06-15 | Tomas Navratil | Chief Development Officer | Automatic Disposition | -1,537 | $130.68 |
| 2026-05-27 | Gilbert Kliman | Independent Director | Other Acquisition | +1,878 | -- |
| 2026-05-27 | Gilbert Kliman | Independent Director | Other Derivative Acquisition | +2,987 | $106.52 |
| 2026-05-27 | Aimee Weisner | Independent Director | Other Acquisition | +1,878 | -- |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
格劳科斯眼科 讨论区 0 条评论